Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study
Diagnosis of advanced or metastatic breast cancer.
Indication for therapy with Cyclin-dependent Kinase 4/6 Inhibitor, as clinical practice;
Age of 18 years or older;
Signing Informed Consent.
You may not be if
Pregnant or breastfeeding women.
Clareo Health | Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study
